Skip to main
ARAY

Accuray (ARAY) Stock Forecast & Price Target

Accuray (ARAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Accuray is a radiation oncology company that develops and sells precise treatment solutions for cancer patients, with its technology, the CyberKnife, being a key competitor in the market. However, lower revenue and higher costs for logistics and parts may impact the company's product and service gross margins, and lumpy quarters and geopolitical uncertainty make it difficult to forecast Accuray's results. Despite trading below its peers and possessing strong technology, Accuray may face challenges in the near future due to macroeconomic factors and operational execution.

Bears say

Accuray is facing numerous challenges as they struggle with declining revenue, geopolitical uncertainty, and a lack of progress on operating improvements and profitability metrics. While efforts have been made to cut costs and improve profitability, it does not appear to be enough to offset the impact of these challenges. Unfortunately, with the current market conditions and lack of visibility into a potential turnaround, it may be best to take a neutral stance on the stock.

Accuray (ARAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accuray (ARAY) Forecast

Analysts have given Accuray (ARAY) a Buy based on their latest research and market trends.

According to 2 analysts, Accuray (ARAY) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accuray (ARAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.